Authors: Andrea E. Gordon, M.D., and Allen F. Shaughnessy, Pharm.D., Harrisburg Family Practice Residency, Harrisburg, Pennsylvania
Saw palmetto is an herbal product used in the treatment of symptoms related to benign prostatic hyperplasia. The active component is found in the fruit of the American dwarf palm tree. Studies have demonstrated the effectiveness of saw palmetto in reducing symptoms associated with benign prostatic hyperplasia. Saw palmetto appears to have efficacy similar to that of medications like finasteride, but it is better tolerated and less expensive. There are no known drug interactions with saw palmetto, and reported side effects are minor and rare. No data on its long-term usage are available. The herbal product also has been used to treat chronic prostatitis, but currently there is no evidence of its efficacy. (Am Fam Physician 2003;67:1281-3.)
Saw palmetto, also known as Serenoa repens or Sabal serrulatum, is an herb that is most commonly used to treat problems related to benign prostatic hyperplasia (BPH). The medicinal element of saw palmetto is taken from the partially dried ripe fruit of the American dwarf palm tree, which is indigenous to the coastal regions of the southern United States, from the Carolinas and Florida to California.
BPH is a nearly universal result of the aging process in men. As the prostate gland enlarges, it can cause both obstructive and irritative symptoms; however, the size of the prostate gland is not predictive of the symptoms that patients experience. Saw palmetto is widely used in other countries; for example, it is used in 50 percent of treatments for BPH in Italy and in 90 percent of such treatments in Germany.1 The active part of the plant is the sterols and free fatty acids found in the berry. The particular solvent used in the extraction process affects the resulting formulation of the product. The most widely studied form of saw palmetto is Permixon, which uses the solvent hexane; other formulations have used ethanol, methanol, and liquid carbon dioxide as solvents. Historically, saw palmetto was administered with pumpkin seeds, and some modern formulations include these elements.
It is unclear which components are the most active, and the mechanism of action is not fully understood. Some of the mechanisms proposed include anti-inflammatory activity,2 blocked conversion of testosterone to dihydrotestosterone (DHT),3,4 and prostate epithelial involution similar to effects noted with the use of finasteride (Proscar).5
Relief of Symptoms
Treatments for BPH can be evaluated by their effect on symptoms such as diminished urine stream, post-void dribbling, overflow incontinence, and urinary retention, or by less useful measures such as urine flow rate, changes in prostate size, and residual volume. In a Cochrane Review, investigators conducted a meta-analysis of randomized controlled studies comparing saw palmetto with placebo or other drugs.6 [Evidence level A: systematic review of randomized controlled trials (RCTs)] The review combined the results of 21 trials with durations of four to 48 weeks. The 21 studies included a total of 3,139 men with a mean age of 65 years (range: 40 to 88 years). According to the International Prostate Symptom Scale, these men had moderate symptoms, with an average urologic score of 14.4 points out of a possible 35 (moderate BPH symptoms range from eight to 19).6 In the 13 studies that reported symptom scores, saw palmetto improved symptom scores, individual symptoms, and flow measures more than placebo. Patients and physicians were more likely to report improvement in symptoms with saw palmetto treatment than with placebo. In the 12 studies that reported nocturia results, saw palmetto reduced nocturia by 25 percent compared with placebo.
In two studies, saw palmetto and finasteride had similar positive effects on urinary symptom scores and peak urine flow. Adverse effects caused by saw palmetto were mild and infrequent and comparable to side effects from placebo. Withdrawal rates among patients receiving placebo, saw palmetto, and finasteride were 7.1, 8.9, and 9.0 percent, respectively.
Results similar to those in the Cochrane Review were produced by a more recent review.7 [Evidence level A: RCTs] Saw palmetto has not been compared with surgical approaches in the treatment of BPH. Saw palmetto is also widely used for treatment of chronic prostatitis, although scientific evidence of benefit is lacking. Contraindications, Adverse Effects, and Interactions The primary side effect occurring in humans is gastrointestinal distress, which is mild and can be minimized by taking saw palmetto with food. Saw palmetto is believed to be quite safe, although formal toxicology studies have not been completed. One study8 found no mutagenic or teratogenic effects in rats and dogs that were fed saw palmetto in a dosage of 2 g per kg daily for six months, and this dosage was well tolerated. No clinically relevant changes in laboratory parameters have been found in human clinical trials.9
There has been some concern that saw palmetto could mask prostate cancer by lowering prostate-specific antigen (PSA) levels. However, a randomized study10 of more than 1,000 patients did not demonstrate this effect on PSA levels. The same study showed that finasteride decreased PSA levels by 41 percent.
Clinical studies have used a dosage of 160 mg twice daily or 320 mg once daily of a lipophilic extract containing 80 to 90 percent of the volatile oil. A daily dosage of 480 mg was not found to be any more effective in a six-month study of dosages.8 Teas are not considered to be effective because they do not contain the volatile oils. The whole berries can be used at the recommended dosage of 1 to 2 g daily.11 As with most herbal medications, the recommended dosage for saw palmetto may vary because of the lack of standardization of such products in the United States. There are no known drug interactions with saw palmetto.
Saw palmetto is an effective treatment for the symptoms of BPH. It appears to be as effective as finasteride and is better tolerated, less expensive, and less likely to decrease PSA levels. No research has evaluated the effect of saw palmetto on long-term outcomes in patients with BPH. Table 1 reviews the efficacy, safety, and tolerability of saw palmetto.
Table 1 – Key Points About Saw Palmetto
|Efficacy||Reducing symptoms of BPH: effective Treatment of chronic prostatitis: evidence lacking.|
|Adverse Effects||Mild gastrointestinal distress: infrequent Not known to interfere with the diagnosis of prostate cancer.|
|Interactions||No known drug interactions.|
|Dosage||Varies; most studies have used 160 mg twice daily or 320 mg once daily.|
|Bottom Line||Safe herbal medicine; effective for treatment of symptoms of BPH.|
BPH = benign prostatic hyperplasia.
The authors indicates that they do not have any conflicts of interest. Source of funding: none reported.
Andrea E. Gordon, M.D., is on the faculty of the Harrisburg Family Practice Residency, Harrisburg, Pa. She received her medical degree from Jefferson Medical College in Philadelphia. Dr. Gordon completed a family practice residency program at the University of Connecticut, Hartford, and a fellowship in family practice faculty development at St. Margaret Memorial Hospital, Pittsburgh, Pa. She is currently enrolled in an integrative medicine fellowship at the University of Arizona, Tucson.
Allen F. Shaughnessy, Pharm.D., is director of research and associate director of the Harrisburg Family Practice Residency. He completed his doctorate and fellowship training at the Medical University of South Carolina, Charleston. Address correspondence to Andrea E. Gordon, M.D., Harrisburg Family Practice Residency, 2501 N. Third St., Harrisburg, Pa., 17110-2098.
1. Di Silverio F, D’Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-14.
2. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996;48:12-20.
3. Briley M, Carilla E, Roger A. Inhibitory effect of Permixon on testosterone 5a-reductase activity of the rat ventral prostate. Br J Pharmacol 1984;83 (suppl):401P.
4. Marks LS, Hess DL, Dorey FJ, Macairan ML, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001;57:999-1005.
5. Marks, LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451-6.
6. Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;3:CD001423.
7. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58:960-4.
8. Small JK, Bombardelli E, Morazzoni P. Serenoa repens (Bartram). Fitoterapia 1997;68:99-113.
9. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-95.
10. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29: 231-40.
11. Saw palmetto monograph. The Natural Medicines Comprehensive Database. www.naturaldatabase.com. Accessed December, 2002.